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Role of combination therapy with ACE inhibitors and calcium “near-terminal cardiac failure.” Indeed, the prevalence
channel blockers in renal protection. Over recent years, a of echocardiographic and clinical manifestations of car-
target blood pressure of 125/75 mm Hg has been sought in diovascular disease is already high at the beginning oforder to reduce the rate of chronic renal disease (CKD) pro-
renal replacement therapy. Data from a Canadian echo-gression and cardiovascular mortality. Some antihypertensive
cardiographic evaluation of 432 patients starting dialysisagents, such as angiotensin converting enzyme (ACE) inhibi-
tors, angiotensin II receptor antagonists and calcium channel showed that only 16% had a normal echocardiogram [2].
blockers also may be capable of reducing CKD progression This suggests that the mechanisms leading to cardiovas-
because they halt some of the pathogenetic mechanisms in- cular impairment have been operating early in the pre-volved in renal damage. The possibility that combination treat-
dialysis phase of CKD. Levin et al found that left ventric-ments with ACE inhibitors and calcium-channel blockers may
ular hypertrophy prevalence is already high in patientsconfer additive or even synergistic renoprotective effects other
than blood pressure control is not only fascinating, but also with mild chronic renal failure (CRF; about 30% in pa-
particularly important because multidrug antihypertensive reg- tients with creatinine clearance of 50 to 75 mL/min) and
imens are required to obtain adequate blood pressure in the
significantly increases with declining of renal function [3].majority of patients with CKD. This combination may provide
Considering these striking numbers, CKD has been de-better blood pressure control, appears to be better tolerated
with fewer side effects than either drug alone, and may exert fined as “a vasculopathic state” [4]. Indeed, a number
a greater renoprotective effect in patients at risk for renal of large-scale trials identified an increase in serum creati-
failure than either an ACE inhibitors or a calcium channel nine as an important cardiovascular risk factor [5–7].
blocker. However, the current available data are too few to
Thus, care must be taken to treat the cardiovascularconfirm this hypothesis. Cardiovascular disease accounts for
risk factors optimally in CKD patients. For this reason,more than 50% of the deaths of hemodialysis patients. Thus,
care must be taken to prevent and treat the cardiovascular risk in addition to the correction of anemia and hyperphos-
factors optimally from the early phase of CKD, and for this phoremia, effective antihypertensive therapy is the single
reason effective antihypertensive therapy is the most important most important treatment in these patients, not only intreatment, not only in order to delay CKD progression, but
order to delay CKD progression, but also to reduce thealso to reduce the burden of cardiovascular disease. In this
burden of cardiovascular disease.perspective combination therapy with ACE inhibitors and cal-
cium channel blockers can give further advantages. However, over recent years it has become clear that
not all antihypertensive agents are equally effective in slow-
ing CKD progression, and that some may have an addi-
Hypertension, together with proteinuria, is probably tional renoprotective effect that is at least partially inde-
one of the major factors contributing to progression of pendent of blood pressure reduction.
chronic kidney disease (CKD), and it is also a significant Similarly, not all antihypertensive drugs display the
determinant of morbidity and mortality among hemodi- same properties in preventing cardiovascular disease or
alysis patients. It is well known that cardiovascular dis- in reducing mortality. ACE inhibitors (ACEIs) reduce
ease accounts for more than 50% of the deaths of hemo- mortality by 19 to 25% in patients with acute myocardial
dialysis patients and, as Silverberg et al pointed out some infarction and left ventricular dysfunction with a poten-
years ago [1], patients afflicted by end-stage renal disease tial of 12 to 42 lives saved per 1000 patients treated per
(ESRD) have already reached, or are going to reach, year [8]. In addition, they reduce complications of acute
myocardial infarction such as congestive heart failure
and may prevent its recurrence [8]. More recently, theKey words: angiotensin converting enzyme inhibitors, angiotensin II
Heart Outcomes Prevention Evaluation (HOPE) studyreceptor antagonists, calcium channel blockers, chronic kidney disease,
combination therapy, hypertension, proteinuria, cardiovascular risk. showed that these agents also significantly reduce the
rates of death, myocardial infarction, and stroke in a broad 2002 by the International Society of Nephrology
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range of patients at high risk for cardiovascular events Bohlen concerning the antiproteinuric capacity of differ-
ent antihypertensives in diabetic nephropathy [14]. De-in the absence of left ventricular dysfunction or heart fail-
ure [9]. Angiotensin II receptor antagonists (ATIIRAs) spite similar degrees of blood pressure reduction, pro-
teinuria tends to decrease more with ACEIs (an averageprobably display similar properties. Results of the Losar-
tan Intervention for Enpoint reduction in hypertension of 45%) than with conventional therapy (an average of
23%) or CCBs other than nifedipine (an average of 35%).(LIFE) study indicated that losartan prevented more
cardiovascular morbidity and death than atenolol for a Furthermore, ACEIs reduced proteinuria by 28% with-
out any change in blood pressure and variations of 1.5%similar reduction in blood pressure in 9123 patients with
essential hypertension [10]. thereafter were observed for each percent change in blood
pressure, whereas proteinuria began to decrease onlyAs shown by a quantitative overview of actively con-
trolled trials in hypertension, compared to older drugs after a mean blood pressure reduction of 5% in the pa-
tients receiving conventional therapy. Moreover, accord-and ACEIs, calcium channel blockers (CCBs) probably
provide more reduction in the risk of stroke but less ing to this meta-analysis [14], after a decrease in mean
blood pressure of approximately 20 mm Hg, the antipro-reduction in risk of myocardial infarction [11]. CCB use
also has been associated with a lower risk of total and teinuric effect of all of the drugs becomes the same.
Figure 1 depicts a clear relationship between systoliccardiovascular mortality among ESRD patients [12].
Furthermore, increasing evidence supports the notion blood pressure achieved during follow-up and proteinuria
levels in the patients enrolled in the angiotensin-convert-that the combination of some of these agents may have
additive or even synergistic effects in delaying CKD pro- ing-enzyme inhibition in progressive renal insufficiency
(AIPRI) study [15], a large randomized controlled studygression and to prevent, or at least reduce, the burden
of cardiovascular disease. This is of particular interest that was aimed at testing the effect of benazepril on
the progression of chronic nephropathies (mainly non-because it is not possible to control blood pressure with
one agent alone in the majority of patients with renal diabetic). As expected, proteinuria is directly related to
systolic blood pressure. Interestingly enough, patientsdisease.
For this reason, it is important, not only to identify treated with ACEIs seem to have lower proteinuria levels
than those treated with placebo even at lower systolic bloodthe antihypertensive agent of first choice, but also to clarify
whether the combination of various agents can offer a pressure values, suggesting an additional effect of ACE
inhibition in comparison with conventional antihyper-further renoprotective advantage beside the achievement
of target blood pressure. tensive agents that is not due to blood pressure reduction.
ACE INHIBITORSBLOOD PRESSURE AND
PROTEINURIA INTERACTION Various experimental data have clearly demonstrated
that the activation of the renin-angiotensin system canAlthough the mechanisms leading to proteinuria in
CKD are complex and not yet fully elucidated, there is promote intraglomerular and systemic hypertension, and
thus contribute to hemodynamically-mediated renal in-certainly a clear relationship between urinary protein
excretion and blood pressure levels. Essential hyperten- jury. Furthermore, angiotensin II, which is the principal
mediator of the major effects of this system, can inducesive patients often have increased urinary protein excre-
tion even in the absence of established renal damage, mesangial and tubular cells to proliferate by means of a
direct or indirect mechanism, and possibly leads to ma-and it correlates with blood pressure levels. This increase
in proteinuria has been attributed to the transmission of trix production and tubulointerstitial fibrosis.
According to the results of large trials, ACEIs reducehigh systemic pressure to the glomeruli and, according
to this hypothesis, any antihypertensive therapy is capa- the rate of loss of renal function in diabetic [16] and
non-diabetic chronic renal diseases [15, 17]; this effectble of decreasing proteinuria when hypertension is pres-
ent. In this regard, a multivariate analysis of controlled is greatest in patients with substantial proteinuria at
baseline. The renoprotective action of ACEIs also hasand uncontrolled trials by Maki et al has shown that
each 10 mm Hg reduction in blood pressure decreases recently been confirmed by a meta-analysis of patient-
level data [18], including 11 randomized trials and a totalproteinuria by 14% (regression coefficient 0.14; 95%
confidence interval0.22 to0.06) [13]. However, there of 1860 patients with non-diabetic chronic renal diseases.
A 30% reduction in the relative risk of developing theseems to be a clear difference in the antiproteinuric ca-
pacity of the different classes of antihypertensive drugs, combined end-point of doubling of the baseline serum
creatinine concentration or ESRD was observed in thosewith ACEIs and non-dihydropyridine (ndh) CCBs hav-
ing the greatest capacity of reducing urinary protein ex- treated with ACEIs in comparison with those treated
with standard antihypertensive treatment. Patients withcretion. This difference very clearly emerges from the
results of a meta-analysis by Weidmann, Schneider and greater proteinuria at baseline benefited more from ACEI
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Fig. 1. Relationship between systolic blood
pressure achieved during follow-up and pro-
teinuria levels in the Angiotensin-Converting-
Enzyme Inhibition in Progressive Renal In-
sufficiency (AIPRI) study [14]. Proteinuria is
directly related to systolic blood pressure, but
patients treated with ACEIs have lower pro-
teinuria levels than those treated with placebo
even at lower systolic blood pressure values.
Symbols are: (, dotted line) benazepril group;
(, solid line) placebo group.
therapy. However, as also underlined by this meta-analy- effect of a number of cytokines and growth factors that
use changes in intracellular free Ca for signal transduc-sis, in the majority of the studies the systolic and diastolic
tion [20]. Furthermore, CCBs appear to reduce cell mem-blood pressure values achieved with ACEIs were lower
brane damage secondary to oxygen free radical forma-than those obtained during standard hypertensive ther-
tion and the activation of phospholipases, as well asapy. Thus, none of these studies have completely an-
the angiotensin II-mediated increase in the mesangialswered the question as to how much the renoprotective
trafficking of macromolecules [20].effect of ACEIs is independent of blood pressure reduc-
However, despite these theoretical and experimentaltion. However, it emerges very clearly that in any case
attributes, the clinical evidence for the renoprotectiveit is necessary to add these agents to standard antihyper-
efficacy of CCBs has been less consistent. A number oftensive treatment in order to obtain an adequate blood
meta- and post-hoc analyses of clinical trials designed topressure control.
detect the effects of ACEIs on CKD progression haveA second limitation of these studies is that they were
revealed that some CCBs can reduce proteinuria [13, 14,designed before the awareness of the need for strict
21]. This effect seems to be at least partially independentblood pressure control in order to slow down CKD pro-
of blood pressure reduction, but it is not uniform forgression, and so none of them were aimed at reaching
every type of CCB. Indeed, while ndh-CCBs seem tothe currently accepted target blood pressure of 125/75
consistently reduce or blunt the rise in proteinuria, dihy-mm Hg. For this reason, it is still unclear whether they
dropyridine (dh) CCBs, regardless of their duration ofare really superior to other antihypertensive agents when
action, tend to have neutral effects on proteinuria. Thislow blood pressure values are achieved.
observation is supported by most literature.
In the already-mentioned multivariate analysis of con-
CALCIUM CHANNEL BLOCKERS trolled and uncontrolled trials involving patients with
Calcium channel blockers are effective vasodilators diabetic and non-diabetic renal diseases by Maki et al
and blood pressure lowering agents, and have been ex- [13], ndh-CCBs together with ACEIs were capable of
tensively used in patients with CKD. CCBs also have inducing a reduction in proteinuria, whereas dh-CCBs
various properties that might afford renal protection. had no apparent effect on proteinuria. Another meta-
Some of the main mechanisms postulated as mediating analysis confirmed that the type of CCB is an important
the renal protective effects of CCBs include their ability determinant of proteinuric response: nifedipine induced
only a slight decrease in proteinuria (8.0%) despite ato delay renal growth [19] and attenuate the mitogenic
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marked fall in blood pressure (14.3%), whereas other ipine (GITS) [28]. After 21 months of follow-up, despite
similar blood pressure control, only the diltiazem groupCCBs had a significantly greater antiproteinuric effect
(20.7%) with a less evident antihypertensive effect had a significant reduction in proteinuria (57  18
vs. 4  10% in the nifedipine group; P  0.001) with(10.4%) [21].
Caution is needed in evaluating these meta-analyses, improvement in glomerular size-selectivity and change
in IgG clearance. On the other hand, no detectable effectbecause they mainly considered small and not always
prospective studies, with a relatively short period of fol- of nifedipine retard in comparison with either enalapril
or placebo was observed on renal morphology over threelow-up. Furthermore, sodium intake, which has been
shown to be a critical determinant of albuminuria reduc- years in 54 type 1 diabetic patients with albuminuria and
blood pressure below 150/90 mm Hg, indicating that, intion associated with CCBs, has rarely been considered
in these studies. this small cohort, disease evolution appeared unaffected
by treatment with either enalapril or nifedipine [29]. How-The Modification of Diet in Renal Disease (MDRD)
study was not designed to assess the efficacy of CCBs; ever, it is worth noting that advanced glomerular struc-
tural abnormalities were already present at baseline, pos-however, it is perhaps one of the largest trial that has
used these agents. One group of patients was treated sibly affecting the rate of further structural damage and
reducing the magnitude of treatment effectiveness.with the ndh-CCB diltiazem, in order to obtain blood
pressure control and, after four years of follow-up, no Conversely, in 241 patients with non-diabetic renal
disease and randomized to receive either long-actingincrease in renal mortality was found in comparison with
ACEIs [22]. nifedipine or fosinopril, renal survival over three years
of follow-up was significantly worse in the CCBs thanBakris et al found that verapamil, another ndh-CCB,
had similar effects to those of lisinopril in reducing the in the ACEIs group [30]. This went together with a 57%
mean decrease in proteinuria in the fosinopril group andrate of CKD progression and proteinuria in 52 patients
with type 2 diabetes [23]. Similarly, in a small, long-term, a 7% mean increase in the group receiving nifedipine.
During follow-up, however, the patients receiving ACEIsprospective randomized trial involving African Ameri-
cans with type 2 diabetes and nephropathy, verapamil showed systolic blood pressure values 4 to 6 mm Hg
lower than those receiving the CCBs, possibly contribut-was found to reduce the decline in renal function and
proteinuria to a greater extent than a -blocker, despite ing to the different outcome in the arm receiving the
ACEIs. By logistic regression analysis, the positive effectcomparable blood pressure reduction [24]. On the other
hand, in the same subset of patients, isradipine (a dh- of fosinopril remained when the data were adjusted for
blood pressure levels. As Marin et al correctly pointedCCB) increased proteinuria by about 50% from baseline
[25]. Another small prospective study [26] of 28 patients out, no clear difference between the two treatments was
observed during the first year of follow-up, probablywith type 2 diabetes found that, although less effective
than enalapril in reducing microalbuminuria, nitrendi- because fosinopril, like every ACEI, induces an initial
functional fall in GFR [30]. Thus, this finding stresses thepine (another dh-CCB) was associated with a greater
increase in GFR after six months of follow-up; however, importance of an adequate follow-up period in studies
aimed at testing the renoprotective effect of antihyper-it needs to be remembered that the beneficial effect of
ACEIs is often preceded by a transient decrease in GFR. tensive drugs.
The different renal outcomes and proteinuric effectsInterestingly enough, the results of a post-hoc analysis
of the double-blind placebo-controlled Systolic Hyper- of dh-CCBs and ndh-CCBs may be related to the fact
that they do not inhibit the same calcium channel. Thetension in Europe (Syst-Eur) Trial showed that in older
patients with isolated systolic hypertension, antihyper- cell distribution of a given calcium channel may vary de-
pending on the type of the inhibited channel [31]. Indeed,tensive treatment starting with nitrendipine decreased
by 64% the incidence of mild renal dysfunction (defined it has been reported that the dh L-type CCBs have an
adverse impact on glomerulosclerosis in the remnantas serum creatinine 176.8 mmol/L; P  0.04) and that
of proteinuria by 33% (P  0.03) [27]. Active treatment kidney model despite significant blood pressure reduc-
tion [32]. Conversely, mibefradil, a CCB with significantreduced the risk of proteinuria more in diabetic than in
non-diabetic patients. Although these beneficial effects antiproliferative activity and a tenfold greater selectivity
for T- compared with L-type channels, provides renopro-can be explained on the basis of blood pressure reduction
achieved with active therapy, it is at least clear that tection in several animal models [33, 34]. However, the
same agent failed to significantly reduce glomerular scle-therapy with CCBs is better than no therapy.
To clarify the issue whether the differential antipro- rosis despite significant reduction in blood pressure in
the rat remnant kidney model [35]. The reasons for theteinuric effects of CCBs may be explained by their effect
on glomerular membrane permeability, Smith et al studied differences between studies are not readily apparent.
However, it is possible that the models differ in their21 patients with type 2 diabetes and nephropathy, who
were randomized to receive either diltiazem CD or nifed- susceptibility to hypertensive renal damage and such dif-
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ferences manifest themselves either as differences in the line proteinuria. In patients with an urinary protein to
blood pressure threshold at which renal damage develop, creatinine ratio of 0.22 (corresponding approximately
and/or differences in the relationship between systemic to a proteinuria of 300 mg/day), the ramipril group
blood pressure load and renal microvascular injury. had a 48% reduced risk of the clinical end-points (reduc-
Indeed, another possible explanation of the different tion in GFR of more than 50%, ESRD, or death) and a
action of CCBs is to be sought in renal autoregulation. significantly slower mean decline in GFR in comparison
All CCBs cause vasodilation of the afferent arteriole, with the amlodipine group. In patients without significant
thus allowing the linear transmission of systemic hyper- baseline proteinuria, protein excretion acutely increased
tension into the glomerular capillaries and leading to during the first six months of therapy with amlodipine
hyperfiltration. However, ndh-CCBs and some dh-CCBs
and to a lower extent during the following months. It isalso vasodilate the efferent arteriole and only partially
worth noting that proteinuria also increased slightly inaffect renal autoregulation [36, 37]. Interestingly, even
patients of this subgroup who were treated with ramipril.if amlodipine, a dh-CCB, has not been shown to vasodi-
However, in patients treated with amlodipine, GFR in-late the efferent arteriole, it was more effective than
creased and, despite a gradual GFR decline, which oc-enalapril in reducing proteinuria and glomerulosclerosis
curred after the sixth month of treatment, at three yearsin advanced stages of renal injury in a rat hyperfiltration
it remained above baseline values and slightly highermodel [36], thus suggesting that its renoprotective action
than in the ramipril group. A similar trend in GFR wasdoes not involve a reduction in glomerular capillary pres-
observed also in the subgroup of patients with meansure. However, the same agent was found to be ineffec-
tive in other animal models [33, 35]. baseline GFR 40 mL/min. The rate of GFR decline
The results of clinical studies about the effects of amlodi- during the chronic phase was slightly steeper in the am-
pine on proteinuria and renal function are conflicting as lodipine than in the ramipril group; thus, it remains un-
well. The Irbesartan Diabetic Nephropathy Trial (IDNT) known whether a longer follow-up could have changed
investigated the effects of irbesartan (300 mg daily), am- the results of this analysis. Indeed, a secondary analysis
lodipine (10 mg/daily), or placebo in 1715 hypertensive of the Angiotensin-Converting-Enzyme Inhibition in
patients with nephropathy due to type 2 diabetes for a Progressive Renal Insufficiency (AIPRI) study suggested
mean follow up of 2.6 years [38]. Treatment with irbe- that slowly progressive patients (as was the case of this
sartan was associated with a relative risk of the primary
subgroup without proteinuria) probably need a longercomposite end-point (the doubling of baseline serum
time before recognizing the beneficial effect of ACEIscreatinine, ESRD, or death for any cause) that was 20%
on the rate of decline in GFR [40]. In this study, thelower than that in the placebo group (P 0.02). Patients
rate of progression was initially faster in the benazeprilin the amlodipine group had a similar relative risk of
group, but subsequently it became slower than in thereaching the primary composite end-point than those of
placebo group; the time at which the serum creatininethe control group. It is worth noting that even if these
profiles in the benazepril and placebo groups crosseddata indicate that amlodipine has no additional renopro-
was earlier in relation to the extent of the two-phasetective effect compared with conventional antihyperten-
effect of the drug and rapidity of the progression of thesive treatment, they also indicate that this agent can be
safely used in CKD patients to achieve blood pressure underlying renal disease [40].
control because it does not cause a worsening in renal When the entire cohort of the AASK study was consid-
function. ered, no significant difference in mean GFR decline from
Conversely, the results of an interim analysis of the baseline to three years was observed between the two
African American Study of Kidney Disease and Hyper- treatment groups [39].
tension (AASK) study, a randomized, double-blind trial One possible explanation of these conflicting results
of 1094 African Americans with hypertensive renal dis- could be that, since the majority of CCBs allows the
ease, are not of univocal interpretation [39]. In this study, linear transmission of systemic hypertension into the glo-
patients were randomly assigned to receive amlodipine
merular capillaries, the maximal renoprotective benefits
(5 to 10 mg/day; N  217), ramipril (2.5 to 10 mg/day;
of CCBs may require strict blood pressure control, andN  436) or metoprolol (50 to 200 mg/day; N  441) in
the reports of their lack of efficacy may be partially duea 3 	 2 factorial design, with other antihypertensive
to inadequate control. An artifact also may be introducedagents added to achieve one of two blood pressure goals.
when short-acting CCBs are used, because these mayThe data and safety monitoring board decided to prema-
intermittently leave renal vessels unprotected against highturely terminate the amlodipine arm after the detection
systemic blood pressure, particularly when preglomeru-of worse outcomes in patients receiving amlodipine than
lar vessels are still vasodilated as a result of the drugs’those in the other two arms. However, the effects of
amlodipine on renal function differed according to base- preferential action on the afferent arteriole.
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COMBINATION TREATMENT WITH exerted an additive antiproteinuric effect and delayed
the reduction in GFR in comparison with the two drugsACE-INHIBITORS AND CALCIUM
alone, despite no greater reduction in systemic bloodCHANNEL BLOCKERS
pressure [23].Given that ACEIs can decrease intraglomerular pres-
The same authors published the results of a random-sure whereas the majority of CCBs cannot, and that both
ized open-label study involving 44 patients with type 2drug classes may have important cellular activity through
diabetes and evidence of nephropathy who were treatedthe inhibition of cytokine secretion and action, it has
with trandolapril, verapamil or a combination of bothbeen suggested that their combination could provide
drugs [45]. At similar levels of blood pressure, the reduc-greater benefit than that obtained with each of them alone.
tion in proteinuria from baseline was significantly greaterFurthermore, CCBs seem to have the capability of reduc-
in the patients receiving the combination treatmenting angiotensin II-induced vasoconstriction of the efferent
(62%  10%) than in those receiving trandolaprilglomerular arterioles, of reducing angiotensin II-induced
alone (33  8%) or verapamil alone (27  8%). Noglomerular contraction and of interfering with renal va-
significant differences in GFR were noted after one yearsoconstriction and natriuresis induced by angiotensin II.
of follow-up.It appears then that CCBs act like a non-specific post-
The Nephros Study recently suggested that combina-receptor antagonist of angiotensin II. The combination
tion treatment also may be a favorable option in patientsof ACEIs with CCBs could then, from one side reduce
with non-diabetic renal disease [46]. One hundred andthe generation of angiotensin II (ACEI-mediated effect),
sixty-five patients were randomly assigned to receivefrom the other side interfere with the action of angioten-
ramipril, felodipine or the combination of both for asin II (CCB-mediated effect). Experimental animal stud-
mean of nearly two years. After correction for the acuteies have shown that the adverse effect of nitrendipine
drug effect, the group receiving ramipril plus felodipinemonotherapy on glomerular structure and function may
had a lower loss of GFR in comparison with the felodi-be prevented by the combination of nitrendipine and
pine group, but no significant difference was observed
enalapril when blood pressure is normalized [41]. In sub-
between the ramipril and the combination-therapy group.
totally nephrectomized rats, the combination of ramipril Furthermore, despite a significant rise in albuminuria
and nifedipine has been found to provide protection after two years in the felodipine group, no significant
against the development of glomerulosclerosis, mesan- change was found in the other groups. Another small-
gial proliferation and podocyte enlargement [42]. How- size prospective study of 60 patients with CKD found
ever, the more intense blood pressure reduction obtained that combination treatment with spirapril and isradipine
with the combination of the two drugs partially limit the for 21 months was able to slow down more effectively
conclusions that can be drawn from this study. the rate of GFR decline than the two agents alone (mean
Brown et al studied the effect of the combination of decline of GFR of 0.32, 0.58 and 0.14 mL/min 	
lisinopril and the benzothiazepine CCB TA-3090 on bea- month	 1.73 m2 in the spirapril, isradipine and combina-
gle dogs with alloxan-induced diabetes mellitus [43]. Al- tion group, respectively) [47]. However, this difference
though similar blood pressure values were obtained with was not statistically significant, probably because of large
the single agents alone and the combination, the associa- variation in GFR and a too small sample size. Further-
tion of the two drugs had a greater antiproteinuric effect more, a trend toward a better blood pressure control in
than either of the single agents. Treatment with lisinopril the combination group was observed, further complicat-
and TA-3090 (alone or in combination) also reduced the ing the interpretations of the results.
extent of glomerular hypertrophy. In stroke-prone rat, Even if these findings do not support that combination
the combination of non-hypotensive doses of verapamil treatment is better than ACEI alone, they suggest at
and the ACEI trandolapril attenuates the increase in least that it is equal. This is very important from the
proteinuria and progression to glomerulosclerosis, re- practical point of view, since in patients with CKD the
gardless of the reduction in blood pressure [44]. addition of a CCB to an ACEI is often required to achieve
Several early studies suggested that combination treat- adequate blood pressure control. From this point of
ment with ACEIs and CCBs may be effective also in view, it also should be considered that ACEIs and CCBs
humans by reducing more effectively albuminuria than do not interfere with each other’s antihypertensive action
the respective monotherapies. However, the results are and mutually reduce the frequency of their side effects
difficult to interpret because blood pressure was not low- to some extent.
ered to the same extent in the three interventions. Conse- Altogether these findings provide preliminary evi-
quently, the effect of blood pressure as a confounding dence that combination therapy may have additive (or
factor cannot be ruled out. In any case, in 52 patients even synergistic) effects on proteinuria reduction in pa-
with type 2 diabetes and mild renal failure, Bakris et al tients with diabetic non-diabetic nephropathies, but de-
serve further confirmation in larger studies.found that the combination of lisinopril and verapamil
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